2 completed. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 2 |
| Phase 2 | 1 | Completed 1 |
Follow Mesothelin Expression: new trials by email Literature Review of Mesothelin Expression trials Research Report on Mesothelin Expression
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors LMB-100, Tofacitinib, Mesothelin Expression - Neoplasms With Mesothelin Expression, Epithelioid Mesothelioma | Phase 1 | Completed | National Cancer Institute (NCI) | 19 | 2019-08-29 | 2023-08-01 |
| Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in People With Previously Treated Metastatic and/or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors LMB-100, Nab-Paclitaxel, Mesothelin Expression - Neoplasms, Pancreatic Neoplasms | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 40 | 2016-08-03 | 2022-03-15 |
Adenocarcinoma (1) · Cholangiocarcinoma (1) · Neoplasms (1) · Pancreatic Neoplasms (1)
National Cancer Institute (NCI) (2)
United States (2)